Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) | Novartis | Ongoing | Deferasirox / Defearisox new formula | 2 | CICL670F2201 | King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Daily practice treatment and Influence of Visanne on the patient Assessment of quality of life parameters | Bayer | Completed | Visanne | 4 | VS1101 | King Khalid University Hospital (Riyadh), Soliman Fakeeh Hospital (Jeddah) |
| A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin | Novonordisk | Completed | BIAsp 30 / Metformin | 4 | BIAsp 3968 | King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada) |
| An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting | MSD | Completed | Sitagliptin | 4 | MK0431-263 | Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh) |
| A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD) | Roche | Completed | Pegasys | 4 | MV22009 | King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj) |
| A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan | Novartis | Completed | Vildagliptin / Sulphonylurea / Metformin | 4 | CLAF237A-MAX-AE-02 | Soliman Fakeeh Hospital (Jeddah) |
| A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan. | Novartis | Completed | Vildagliptin /Gliclazide / Metformin | 4 | CLAF237A2411 | King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh) |
| UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER) | Novartis | Completed | Ranibizumab | 4 | CRFB0021 | King Khaled Eye Specialist Hospital (Riyadh) |
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk | Boehringer Ingelheim | Completed | BI 10773 | 3 | 1245.25 | King Fahad Medical City (Riyadh) |
| Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma | Roche | Completed | Bevacizumab | 3 | MO22923 | King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.